BioCentury
ARTICLE | Distillery Therapeutics

Cancer

November 14, 2017 10:57 PM UTC

Cell culture and mouse studies suggest inhibiting EZH2 could help treat KDM6A-mutant MM. In three KDM6A-mutant human MM cell lines, two EZH2 inhibitor tool compounds decreased viability and increased apoptosis compared with an inactive control compound or vehicle. In a xenograft mouse model of KDM6A-mutant MM, one of the EZH2 inhibitors decreased tumor growth compared with vehicle. Next steps could include testing other EZH2 inhibitors in models of KDM6A-mutant MM.

Epizyme Inc. and Eisai Co. Ltd. have the EZH2 inhibitor tazemetostat (E7438; EPZ-6438) in Phase II testing to treat B cell lymphoma, lymphoma, mesothelioma, non-Hodgkin's lymphoma (NHL), sarcoma and solid tumors...